These are the stocks posting the largest moves before the bell.Market Insiderread more
U.S. stock futures pointed to a higher open on Monday as Treasury yields rebounded to quell fears of a possible recession.US Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Amid the headlines of stores closures and retail bankruptcies, it can be tough to accept that the U.S. consumer is doing just fine.Retailread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
Dow to jump; Trump defends economy; Huawei hopes for US reprieve; Trump and Apple's Tim Cook meet; president ties Hong Kong protests to China trade disputeMarketsread more
We tested the best way to cut the airport commute time for New Yorkers. The most expensive of the four options we reviewed, Uber Copter, was only 14 minutes faster than mass...Transportationread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
In the paradoxical world of drug pricing, the first U.S. price tag exceeding $1 million for a medicine is being contemplated as the nation's agita over the cost of prescription drugs climbs ever higher.
New gene therapies that aim to cure hemophilia, a disease affecting the blood's ability to clot, may carry prices of $1.5 million or more, analysts at Leerink wrote in a research note Monday.
Gene therapies deliver a healthy copy of a gene to make up for a defective one that causes disease, aiming to cure — or at least significantly improve — the malady in just one treatment. Such therapies for hemophilia are in development at drugmakers BioMarin, Spark Therapeutics and UniQure.
They're changing the way we think about delivery — and pricing — of medicine. The first gene therapy was approved in the U.S. in December, and received a price tag of $850,000 in January. Called Luxturna, it treats a rare form of blindness and is made by Spark.
A price of $1.5 million or more would set a new paradigm in the U.S.
"It appears the seemingly impervious million-dollar threshold may be breached with hemophilia gene therapy, which could do so while still creating value for society by reducing the cost of factor replacement therapy," Leerink analysts Joseph Schwartz and Dae Gon Ha wrote in their research note.
Factor replacement therapy is the current treatment for people with hemophilia, and is estimated to cost between $580,000 and $800,000 a year for adult patients, according to Leerink. For some patients, costs can approach $1 million a year, or even more. About 20,000 Americans have hemophilia.
For that reason, a potential one-time $1.5 million cost is perceived by many to be a bargain compared with a lifetime of chronic therapy.
Others, though, like Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, see it as excessive.
The Leerink analysts took the price of Spark's gene therapy, Luxturna, into consideration in coming to their price estimate, noting "one of the top questions about gene therapy treatments concerns the price which the market will bear," taking into account direct and indirect costs "as well as societal cost burden of the affliction."
They said there may even be "some headroom" above $1.5 million for hemophilia gene therapies, with the potential for the medicines, if approved, to be priced at $2 million per patient.